---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-018135"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:03:54.853339+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oramed's RoyaltyVest signs exclusive Rest of World license for Scilex lidocaine products ZTlido/SP-103

## Summary
- RoyaltyVest (50% owned by Oramed) obtains exclusive license to develop, manufacture and commercialize ZTlido (lidocaine 1.8%) and SP-103 outside the U.S.
- Revenue share: RoyaltyVest and Scilex Pharma each receive 50% of Net Revenue, paid quarterly by RoyaltyVest.
- Licensee must commit $200,000 annually (or in-kind) and obtain regulatory approval in at least one Major Market Country within 18 months of effective date.
- Scilex Holding Company guaranteed Scilex Pharma's obligations under the license via a parent guarantee; guarantee terminates upon a change of control.
- Oramed transferred 50% of RoyaltyVest shares to Oramed; Oramed controls half of RoyaltyVest's board of directors.

## SEC filing metadata
- accession: 0001213900-25-018135
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390025018135/0001213900-25-018135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390025018135/ea0232360-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-018135
- JSON: https://secwatch.observer/filing/0001213900-25-018135.json
- Plain text: https://secwatch.observer/filing/0001213900-25-018135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.